张文宏团队最新成果发布

Core Viewpoint - A new short-course preventive treatment for tuberculosis (TB) has been developed in China, potentially reducing the treatment duration from three months to one month, which may enhance patient compliance and reduce side effects [1][2][5]. Group 1: Research Background - The study was initiated by Professor Zhang Wenhong's team and published in the journal Emerging Microbes & Infections, focusing on a novel short-course regimen (1H3P3) for TB prevention in silicosis patients [2][3]. - Traditional preventive treatment options in China include 6-9 months of isoniazid monotherapy, 4 months of rifampicin monotherapy, and the 3-month isoniazid and rifapentine combination (3HP) [3][4]. Group 2: Efficacy and Safety of 1H3P3 - The 1H3P3 regimen consists of rifapentine (450mg) and isoniazid (400mg) administered three times a week for four weeks, aiming to lower drug dosage per administration and improve treatment adherence [5][6]. - In a study involving 238 participants, only 2.5% were diagnosed with active TB after three years, indicating a 74% reduction in TB incidence compared to the control group [6][7]. - The safety profile of the 1H3P3 regimen showed that 27.4% experienced adverse events, mostly mild, with only 0.4% experiencing severe adverse events [6][8]. Group 3: Implications for High-Risk Populations - The study primarily focused on silicosis patients, a high-risk group for TB, and the findings suggest that the 1H3P3 regimen could be effective in other high-risk populations [9]. - Future research aims to expand the application of the 1H3P3 regimen to broader high-risk groups, including close contacts of TB patients, and to gather more clinical data to support its safety and efficacy [9].